Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

Earnings create movement and set the trend for a stock for the following three months. A stock can post a blowout quarter and see great movement and a shift from pessimism to optimism (i.e. Netflix, Inc. (NASDAQ:NFLX)) or vise versa. But sometimes, the market gets it wrong and the stock trends in an incorrect direction. Sometimes it creates value and other times it creates a value trap. With that being said, let’s look at the three most obvious cases on Thursday.

Large Pharma Growth is Tough to Come By

We’ve seen several notable trends for this earnings season, and one has been declining revenues and profits for large pharma. The reason has been due to the patent cliff that these companies are enduring, therefore when I saw that Amgen, Inc. (NASDAQ:AMGN) grew by 11% I was very optimistic. The company saw more than 100% revenue growth from its drug Xgeva, to prevent bone injuries in cancer patients, and also 100% growth for Prolia, for osteoporosis. Furthermore, the company increased its EPS guidance, reiterated bullish revenue and CAPEX guidance, and guided for $1 billion in sales in emerging markets.

Despite these strengths, Amgen fell over 1.5% after reporting earnings. The company did miss bottom line expectations, but only by $0.04 and mostly because of acquisition related costs. The stock had been sitting near all-time highs but was not expensive; it traded with a P/E ratio of just 15.50 and a price/sales under 4.0. Therefore, I see no reason for the decline, and believe the pullback could be a great opportunity.

Impressive Performance for an Unimpressive Quarter

Shares of transportation company Con Way Inc (NYSE:CNW) traded higher by over 7% after posting mixed Q4 results. The company beat revenue expectations by $10 million by posting $1.4 billion. The 3.4% revenue growth was very modest, and although encouraging to some, I viewed its EPS miss of $0.03 to be more significant. Sure, its EPS weakness was mostly due to tax items, yet there was nothing impressive from the company to create such a large move higher. The stock is not overvalued by any means, yet I view it as fairly valued because of its modest revenue growth. Therefore, the large move higher could be a bit of a value trap.

The Market Gets this Right … Then Gets it Wrong!

Alcatel Lucent SA (NYSE:ALU) opened in Europe with gains of 8% after posting Q4 earnings that beat expectations, and opened in U.S. markets with gains of 5%. The company reported sales of 4.1 billion euros and a net loss of 1.37 billion euros. However, the large loss was due to a 1.41 billion euro charge. Therefore, the quarter was fairly solid as the company saw 14% growth in North America and 26% growth in its IP division.